Uwe Rix

6.4k total citations · 2 hit papers
89 papers, 4.9k citations indexed

About

Uwe Rix is a scholar working on Molecular Biology, Oncology and Hematology. According to data from OpenAlex, Uwe Rix has authored 89 papers receiving a total of 4.9k indexed citations (citations by other indexed papers that have themselves been cited), including 45 papers in Molecular Biology, 26 papers in Oncology and 17 papers in Hematology. Recurrent topics in Uwe Rix's work include Chronic Myeloid Leukemia Treatments (16 papers), Chronic Lymphocytic Leukemia Research (14 papers) and Microbial Natural Products and Biosynthesis (12 papers). Uwe Rix is often cited by papers focused on Chronic Myeloid Leukemia Treatments (16 papers), Chronic Lymphocytic Leukemia Research (14 papers) and Microbial Natural Products and Biosynthesis (12 papers). Uwe Rix collaborates with scholars based in United States, Austria and Germany. Uwe Rix's co-authors include Giulio Superti‐Furga, Lily L. Remsing Rix, Oliver Hantschel, Keiryn L. Bennett, Jacques Colinge, Jürgen Rohr, Peter Valent, Eric B. Haura, Lily L. Remsing and John M. Koomen and has published in prestigious journals such as Proceedings of the National Academy of Sciences, Journal of the American Chemical Society and Journal of Biological Chemistry.

In The Last Decade

Uwe Rix

89 papers receiving 4.8k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Chemical proteomic profiles of the BCR-ABL inhibitors imatinib, nilotinib, and dasatinib reveal novel kinase and nonkinase targets

2007 532 citations Uwe Rix, Lily L. Remsing Rix et al. profile →
Target profiling of small molecules by chemical proteomics

2008 463 citations Uwe Rix, Giulio Superti‐Furga profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Uwe Rix United States	38	2.6k	1.0k	901	841	833	89	4.9k
Pascal Furet Switzerland	50	5.6k 2.1×	2.4k 2.3×	1.1k 1.2×	2.0k 2.4×	339 0.4×	125	8.6k
William P. Tong United States	40	3.6k 1.4×	2.1k 2.0×	483 0.5×	649 0.8×	294 0.4×	110	6.6k
Judy Lucas United States	34	2.2k 0.9×	1000 1.0×	443 0.5×	1.1k 1.3×	177 0.2×	69	4.1k
Taebo Sim South Korea	31	3.5k 1.3×	1.1k 1.0×	437 0.5×	951 1.1×	222 0.3×	122	5.2k
Alex N. Bullock United Kingdom	49	6.1k 2.3×	2.8k 2.7×	417 0.5×	872 1.0×	145 0.2×	108	8.7k
A. Chaikuad Germany	37	2.9k 1.1×	784 0.7×	210 0.2×	760 0.9×	149 0.2×	123	4.4k
Steven W. Elmore United States	24	3.2k 1.2×	1.2k 1.1×	510 0.6×	716 0.9×	215 0.3×	37	4.8k
Silvia Schenone Italy	43	2.5k 0.9×	737 0.7×	459 0.5×	3.1k 3.7×	381 0.5×	236	5.9k
Christopher L. Morton United States	45	3.2k 1.2×	1.5k 1.5×	204 0.2×	389 0.5×	935 1.1×	128	5.6k
Peter Traxler Switzerland	30	2.7k 1.0×	1.6k 1.5×	357 0.4×	1.1k 1.4×	360 0.4×	61	4.6k

Countries citing papers authored by Uwe Rix

Since Specialization

Citations

This map shows the geographic impact of Uwe Rix's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Uwe Rix with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Uwe Rix more than expected).

Fields of papers citing papers by Uwe Rix

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Uwe Rix. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Uwe Rix. The network helps show where Uwe Rix may publish in the future.

Co-authorship network of co-authors of Uwe Rix

This figure shows the co-authorship network connecting the top 25 collaborators of Uwe Rix. A scholar is included among the top collaborators of Uwe Rix based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Uwe Rix. Uwe Rix is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Xu, Xiaonan, Kaizhen Wang, Eric A. Welsh, et al.. (2024). PTEN Lipid Phosphatase Activity Suppresses Melanoma Formation by Opposing an AKT/mTOR/FRA1 Signaling Axis. Cancer Research. 84(3). 388–404. 8 indexed citations

Chen, Zhihua, Jiannong Li, Eslam Mohamed, et al.. (2021). Targeted Therapy Given after Anti–PD-1 Leads to Prolonged Responses in Mouse Melanoma Models through Sustained Antitumor Immunity. Cancer Immunology Research. 9(5). 554–567. 19 indexed citations

Solanki, Hitendra S., Eric A. Welsh, Bin Fang, et al.. (2021). Cell Type–specific Adaptive Signaling Responses to KRASG12C Inhibition. Clinical Cancer Research. 27(9). 2533–2548. 64 indexed citations

Hu, Qi, Lily L. Remsing Rix, Eric A. Welsh, et al.. (2020). Dissecting the landscape of CAF-mediated drug resistance mechanisms in ALK-rearranged NSCLC. European Journal of Cancer. 138. S48–S48. 2 indexed citations

Faião‐Flores, Fernanda, Michael F. Emmons, Michael Durante, et al.. (2019). HDAC Inhibition Enhances the In Vivo Efficacy of MEK Inhibitor Therapy in Uveal Melanoma. Clinical Cancer Research. 25(18). 5686–5701. 69 indexed citations

Ramello, María C., Brent M. Kuenzi, Daniel N. Santiago, et al.. (2019). An immunoproteomic approach to characterize the CAR interactome and signalosome. Science Signaling. 12(568). 122 indexed citations

Ctortecka, Claudia, Vinayak Palve, Brent M. Kuenzi, et al.. (2018). Functional Proteomics and Deep Network Interrogation Reveal a Complex Mechanism of Action of Midostaurin in Lung Cancer Cells. Molecular & Cellular Proteomics. 17(12). 2434–2447. 17 indexed citations

Vaishnavi, Aria, Laura Schubert, Uwe Rix, et al.. (2017). EGFR Mediates Responses to Small-Molecule Drugs Targeting Oncogenic Fusion Kinases. Cancer Research. 77(13). 3551–3563. 61 indexed citations

Verduzco, Daniel, Brent M. Kuenzi, Fumi Kinose, et al.. (2017). Ceritinib Enhances the Efficacy of Trametinib in BRAF/NRAS -Wild-Type Melanoma Cell Lines. Molecular Cancer Therapeutics. 17(1). 73–83. 13 indexed citations

10.

Woods, Nicholas T., Gabriëla Wright, Lily L. Remsing Rix, et al.. (2016). PAXIP1 Potentiates the Combination of WEE1 Inhibitor AZD1775 and Platinum Agents in Lung Cancer. Molecular Cancer Therapeutics. 15(7). 1669–1681. 21 indexed citations

11.

Li, Jiannong, Bin Fang, Fumi Kinose, et al.. (2016). Target Identification in Small Cell Lung Cancer via Integrated Phenotypic Screening and Activity-Based Protein Profiling. Molecular Cancer Therapeutics. 15(2). 334–342. 18 indexed citations

12.

Knezevic, Claire E., Gabriëla Wright, Lily L. Remsing Rix, et al.. (2016). Proteome-wide Profiling of Clinical PARP Inhibitors Reveals Compound-Specific Secondary Targets. Cell chemical biology. 23(12). 1490–1503. 77 indexed citations

13.

Muellner, Markus K., Barbara Mair, Yasir H. Ibrahim, et al.. (2015). Targeting a cell state common to triple‐negative breast cancers. Molecular Systems Biology. 11(2). 789–789. 23 indexed citations

14.

Bai, Yun, Jae‐Young Kim, Bin Fang, et al.. (2014). Adaptive Responses to Dasatinib-Treated Lung Squamous Cell Cancer Cells Harboring DDR2 Mutations. Cancer Research. 74(24). 7217–7228. 34 indexed citations

15.

Gridling, Manuela, Scott B. Ficarro, Florian P. Breitwieser, et al.. (2014). Identification of Kinase Inhibitor Targets in the Lung Cancer Microenvironment by Chemical and Phosphoproteomics. Molecular Cancer Therapeutics. 13(11). 2751–2762. 20 indexed citations

16.

Winter, Georg, Uwe Rix, Andrej Lissat, et al.. (2011). An Integrated Chemical Biology Approach Identifies Specific Vulnerability of Ewing's Sarcoma to Combined Inhibition of Aurora Kinases A and B. Molecular Cancer Therapeutics. 10(10). 1846–1856. 32 indexed citations

17.

Ubaida‐Mohien, Ceereena, Jürgen Hartler, Florian P. Breitwieser, et al.. (2010). MASPECTRAS 2: An integration and analysis platform for proteomic data. PROTEOMICS. 10(14). 2719–2722. 18 indexed citations

18.

Rix, Uwe, Chenchen Wang, Yihua Chen, et al.. (2005). The Oxidative Ring Cleavage in Jadomycin Biosynthesis: A Multistep Oxygenation Cascade in a Biosynthetic Black Box. ChemBioChem. 6(5). 838–845. 57 indexed citations

19.

Remsing, Lily L., Mohammad Nur‐e‐Alam, Alfredo F. Braña, et al.. (2003). Mithramycin SK, A Novel Antitumor Drug with Improved Therapeutic Index, Mithramycin SA, and Demycarosyl-mithramycin SK: Three New Products Generated in the Mithramycin Producer Streptomyces a rgillaceus through Combinatorial Biosynthesis. Journal of the American Chemical Society. 125(19). 5745–5753. 113 indexed citations

20.

Trefzer, Axel, Dirk Hoffmeister, Eva Künzel, et al.. (2000). Function of glycosyltransferase genes involved in urdamycin A biosynthesis. Chemistry & Biology. 7(2). 133–142. 74 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact